Sanofi: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron's Dupixent has been approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid, a chronic skin disease. The approval is based on a pivotal study showing that Dupixent patients experienced sustained disease remission at a rate over four times higher than those on placebo.
The Ministry of Health, Labour and Welfare in Japan has approved Dupixent for treating adults with moderate-to-severe bullous pemphigoid. This approval is based on the LIBERTY-BP-ADEPT phase 2/3 study, which showed that Dupixent led to sustained disease remission in over four times as many patients as placebo. Bullous pemphigoid is a rare skin disease characterized by intense itch, painful blisters, and lesions. Available treatment options are limited and can add to the disease burden. Dupixent is now approved in Japan for seven indications, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.